Revelation Biosciences (REVBW) Stock Price, News & Analysis

Company Overview

Revelation Biosciences, Inc. (NASDAQ: REVBW) is a clinical-stage molecular diagnostics company focused on the rapid detection of life-threatening bacterial infections. The company leverages next-generation sequencing (NGS) to analyze cell-free microbial DNA in patient blood samples, with an emphasis on early identification of pathogens in bloodstream infections and hospital-acquired pneumonia. By targeting critically ill patients, Revelation Biosciences aims to shorten time to diagnosis and guide more effective antimicrobial therapy.

The company’s technology platform integrates high-throughput DNA sequencing with proprietary bioinformatics algorithms to differentiate pathogenic microbes from background microbial DNA. This approach enables broad, hypothesis-free screening for bacteria, fungi and antibiotic resistance markers without the need for prior culture or targeted assays. Revelation Biosciences is working to validate its assays in clinical studies and to pursue regulatory clearance for use in acute care settings.

Revelation Biosciences is led by a management team experienced in molecular diagnostics, genomics and clinical laboratory operations. The company is headquartered in the United States and concentrates initial commercialization efforts on large academic medical centers and reference laboratories. As it advances toward regulatory approval and market launch, Revelation Biosciences seeks to address critical gaps in the diagnosis and management of sepsis and severe respiratory infections.

Key Stats

• Today's Range: $0.01 to $0.01
• 50-Day Range: $0.0062 to $0.0190
• 52-Week Range: $0.01 to $0.04
• Volume: 141 shs
• Average Volume: 64,497 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 7/24/2026
• Next Earnings (Estimated): 8/07/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:REVBW
• CIK: 1810560
• Web: www.revbiosciences.com
• Phone: 917 622 5800
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A